September 4, 2022, Seminar on How to Break Through the Barriers of Antibody Commercial Production hosted by Hualan Bio & ShengMing Bio and co-organized by their partners was successfully held in Hualan Biological Industrial Park, Plain Demonstration Area, Xinxiang City. 

We were fortunate to invite Mrs. Shibin, Director of SAPA-China to chair the conference, Mrs. Pan Ruowen, Executive Deputy General Manager of Hualan Biological Bacterin Inc. to give a welcome speech, and Mrs. An Wenqi (Member of the Board of Hualan Bio, General Manager of Shengming Bio), Mrs. Wanglan (Researcher of National Institutes for Food and Drug Control), Mr. Lin Jihan (R&D Director of Shanghai Tofflon Science and Technology Co., Ltd), Mr. Xiao Zhihua ( Chairman of the Board of Shanghai OPM Biosciences Co., Ltd ), Mr. Yang Shengjiao (Product Manager of Lisure Science (Suzhou) Co., Ltd ), Mr. Liu Xuping (CEO of Shanghai BioEngine Sci-Tech Co., Ltd), Mr. Tang Yifeng (Implementation Director of Baimosi (Chengdu) Digital Technology Co., Ltd) to conduct speech sharing. 

Next, Shengming Bio held the commencement ceremony of CMFII-30000L production line construction. Mrs. Anwenqi invited Mrs, Pan Ruowen, Mr. Liu qianjin (Deputy General Manager of Austar Group), Mr. Zheng Xiaoyou, Mr. Luoliang (Deputy General Manager of Lisure Science (Suzhou) Co., Ltd ), Mr. Lin Jun (General Manager of Chengdu Shenke Industrial Equipment Installation Co., Ltd ) as the guest representatives to witness the launching ceremony of CMFII-30000L Production Line of Shengming Bio. 

Then, all guests orderly visited the large-scale production line of the CMFII Project of Shengming Bio. The CMFII takes the cGMP of China, the USA, and European as standards, including two same and independent 35000L production lines with the reasonable layout of function areas, thus the production interaction is more flexible. Besides, 18 exhibitors made a stunning appearances, and many old and new friends stopped by to visit and discuss with industry peers in depth.

We appreciated the partners who expressed strong support during the construction of the CMFI& CMFII production platform. 

We believe that this will play an important role in the commercialization cooperation of monoclonal antibodies. We sincerely thank all the co-organizers for their affirmation. We are looking forward to meeting you better!